We are live on ! Find out more
FDMT icon

4D Molecular Therapeutics
FDMT

63 hedge funds and large institutions have $515M invested in 4D Molecular Therapeutics in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 32 increasing their positions, 11 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

191% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 11

175% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 4

29% more capital invested

Capital invested by funds: $400M → $515M (+$115M)

13% more funds holding

Funds holding: 56 → 63 (+7)

8.89% more ownership

Funds ownership: 62.1% → 71% (+8.9%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $2K

Holders
63
Holders Change
+7
Holders Change %
+12.5%
% of All Funds
1.1%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
11
Increased
32
Reduced
11
Closed
4
Calls
–
Puts
$2K
Net Calls
-$2K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$20.2M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$13.6M
3
CC
Centiva Capital
New York
+$10.2M
4
JP Morgan Chase
JP Morgan Chase
New York
+$6.18M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$4.98M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$5.61M
2
Morgan Stanley
Morgan Stanley
New York
-$1.78M
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$901K
4
ACH
ArrowMark Colorado Holdings
Colorado
-$754K
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$531K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$1.87M +$1.16M +40,582 +142%
EHI
27
Eagle Health Investments
Connecticut
$1.54M – – –
PPA
28
Parametric Portfolio Associates
Washington
$1.15M +$296K +10,374 +32%
Swiss National Bank
29
Swiss National Bank
Switzerland
$798K +$257K +9,000 +44%
RhumbLine Advisers
30
RhumbLine Advisers
Massachusetts
$662K +$429K +15,031 +158%
California State Teachers Retirement System (CalSTRS)
31
California State Teachers Retirement System (CalSTRS)
California
$600K +$248K +8,707 +64%
Deutsche Bank
32
Deutsche Bank
Germany
$454K +$177K +6,220 +58%
SG Americas Securities
33
SG Americas Securities
New York
$383K +$141K +4,932 +53%
MFS
34
Mirabella Financial Services
United Kingdom
$380K +$402K +14,080 New
Citadel Advisors
35
Citadel Advisors
Florida
$373K -$384K -13,476 -49%
State of Wisconsin Investment Board
36
State of Wisconsin Investment Board
Wisconsin
$345K +$114K +4,014 +46%
Bank of America
37
Bank of America
North Carolina
$341K +$45.9K +1,608 +15%
Victory Capital Management
38
Victory Capital Management
Texas
$331K -$3.74K -131 -1%
M&T Bank
39
M&T Bank
New York
$314K +$32.9K +1,153 +11%
AIG
40
American International Group
New York
$309K +$170K +5,964 +108%
Manulife (Manufacturers Life Insurance)
41
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$301K +$319K +11,178 New
Goldman Sachs
42
Goldman Sachs
New York
$261K +$276K +9,686 New
RA
43
Resolute Advisors
California
$259K – – –
New York State Common Retirement Fund
44
New York State Common Retirement Fund
New York
$256K +$49.4K +1,734 +22%
CS
45
Credit Suisse
Switzerland
$241K +$255K +8,945 New
VOYA Investment Management
46
VOYA Investment Management
Georgia
$220K +$232K +8,150 New
MIM
47
MetLife Investment Management
New Jersey
$215K +$228K +7,979 New
Wells Fargo
48
Wells Fargo
California
$206K +$196K +6,859 +831%
VEA
49
Virtus ETF Advisers
New York
$196K -$11K -385 -5%
MLICM
50
Metropolitan Life Insurance Company (MetLife)
New York
$163K +$172K +6,037 New
1
2
3

FDMT Hedge Fund Activity: Q3 2021 in Review

63 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q3 2021, worth a combined $515M — up 29% from $400M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new FDMT positions and 4 closed out — a net gain of 7 holders — while 32 added to existing stakes and 11 trimmed.

The largest buyer was BlackRock, adding an estimated $20.2M. The largest seller was Millennium Management, cutting an estimated $5.61M.

  • 63 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q3 2021, up from 56 in Q2 2021.
  • Funds reported $515M of 4D Molecular Therapeutics stock for Q3 2021, up 29% quarter-over-quarter.
  • 11 funds opened new 4D Molecular Therapeutics positions in Q3 2021 and 4 closed out, a net change of +7 holders.
  • The largest 4D Molecular Therapeutics buyer in Q3 2021 was BlackRock, an estimated $20.2M added.
  • The largest 4D Molecular Therapeutics seller in Q3 2021 was Millennium Management, an estimated $5.61M sold.

Based on aggregated 13F filings for Q3 2021.